Compare Oscar Health Inc (OSCR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Repligen Corporation Common Stock — how do they compare? Oscar Health Inc trades at $34.42 (market cap $10.43B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Oscar Health Inc and Repligen Corporation Common Stock are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Repligen Corporation Common Stock for 0 Days on average.
| OSCR | RGEN | |
|---|---|---|
Market Cap | $10.43B | $11.14B |
Volume | 5,467,402 | 1,259,263 |
Sector | Health | Health |
52-Week High | $34.32 | $194.57 |
52-Week Low | $10.85 | $102.87 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $6.79B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent analyst upgrades to Strong Buy reflect optimism about expanded market opportunities and margin expansion potential.
The stock presents growth potential with consensus price target of $34.75 offering modest upside. Key risks include rising medical costs threatening profitability and competitive ACA market pressures. Institutional interest remains strong with recent purchases, supporting the bullish technical outlook despite RSI indicating potential near-term overbought conditions.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
